MARKET

NVTA

NVTA

Invitae
NYSE

Real-time Quotes | Nasdaq Last Sale

13.67
-0.52
-3.66%
After Hours: 13.42 -0.25 -1.83% 18:46 03/31 EDT
OPEN
14.22
PREV CLOSE
14.19
HIGH
14.76
LOW
13.27
VOLUME
1.84M
TURNOVER
--
52 WEEK HIGH
28.75
52 WEEK LOW
7.42
MARKET CAP
1.35B
P/E (TTM)
-5.2114
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of NVTA and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average NVTA stock price target is 31.08 with a high estimate of 32.00 and a low estimate of 30.00.

EPS

NVTA News

More
  • Invitae (NVTA) Gains But Lags Market: What You Should Know
  • Zacks · 1d ago
  • Why Invitae Skyrocketed 20.5% Today
  • MotleyFool.com · 6d ago
  • Invitae (NVTA) Stock Moves -0.59%: What You Should Know
  • Zacks · 03/23 22:45
  • Invitae and Muscular Dystrophy Association (MDA) Expand Access to No-Charge Genetic Testing in the U.S. and Canada
  • PR Newswire · 03/23 12:30

Industry

Biotechnology & Medical Research
-0.26%
Pharmaceuticals & Medical Research
-0.17%

Hot Stocks

Symbol
Price
%Change

About NVTA

Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. As of December 31, 2016, the Company's products consisted of assays totaling over 1,100 genes that could be used for multiple indications, including hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders and other hereditary conditions. The Company offers panels for a range of hereditary conditions in cancer, cardiology, neuromuscular, pediatric and rare diseases. The Company focuses on genetic testing, genome network and genome management. The Company offers full gene sequencing and deletion/duplication analysis as a standard for all of its tests. The Company holds interests in AltaVoice, a patient-centered data company.
More

Webull offers kinds of InVitae Corp stock information, including NYSE:NVTA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVTA stock news, and many more online research tools to help you make informed decisions.